PharmaLegacy

Executive Summary

PharmaLegacy is a China-based preclinical contract research organization (CRO) that provides comprehensive pharmacology services to support drug development. Founded in 2020, the company has rapidly built an extensive portfolio of over 1,500 validated animal models across more than 100 therapeutic indications, with particular expertise in oncology, immunology, and small molecule therapeutics. Their core offerings include in vitro and in vivo testing platforms for candidate screening and IND-enabling studies, enabling pharmaceutical and biotech clients to accelerate their drug discovery programs. By operating at the preclinical stage, PharmaLegacy addresses a critical bottleneck in the drug development pipeline, offering scalable and specialized services that reduce costs and timelines for its customers. As a private company with 50–200 employees, PharmaLegacy is well-positioned to capture growing demand for outsourced preclinical services, particularly from Western and Asian clients seeking high-quality, cost-effective alternatives. Its competitive edge lies in the breadth and validation of its animal models, which span oncology, immunology, metabolic diseases, CNS, ophthalmology, infectious diseases, cardiovascular, and more. With the increasing complexity of drug development and the trend toward outsourcing, PharmaLegacy is poised for continued growth. The company may also expand into new therapeutic areas or invest in advanced platforms such as humanized mouse models to further differentiate itself in the preclinical CRO market.

Upcoming Catalysts (preview)

• Q4 2026Major partnership or contract with a top pharmaceutical company30% success
• Q2 2027Expansion into new therapeutic areas or advanced model platforms (e.g., humanized mice)40% success
• Q1 2027Series A or B funding round to scale operations50% success